Abstract: A simple and efficient method for separating migrasomes from macrophages is provided. The method separates migrasomes having a diameter range of 0.5 micrometers (?m) to 3 ?m by intercepting through a filter and eluting through reverse filtration successfully. The separated migrasome has a vesicle-liked structure and wrinkles on its surface, and the separated migrasome has a diameter over 500 nanometers (nm). The separated migrasomes express their characteristic proteins PIGK, EOGT, and TSPAN4, but do not express specific markers TSG101 and ALIX of EVs, indicating that the separated migrasomes are a unique type of vesicles distinct from extracellular vesicles (EVs). The integrity of ribonucleic acids (RNA) carried by the migrasomes is not affected. The method for separating migrasomes from macrophages has the characteristics of simplicity, high efficiency, good controllability, good repeatability, and low cost, and large special equipment is not needed.

Abstract: Interface circuitry of an apparatus receives a first service data packet that includes at least first information for a first multimedia presentation frame and second information for a second multimedia presentation frame. Processing circuitry of the apparatus stores the first information and the second information in different rows having different row number in a service data table. Then the processing circuitry determines, from a preset database, first material data for the first multimedia presentation frame and second material data for the multimedia presentation frame based on material configuration information in the first service data packet. Further the processing circuitry associates the first material data and the second material data in a material data table with different row numbers in the service data table and generates first multimedia service data corresponding to the first service data packet based on the association between the service data table and the material data table.

Abstract: Provided are a compound as represented by structural formula (I) ({5-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-6-aminopyridazin-3-yl}-N-{4-[((3S,5R)-3,5-di methylpiperazinyl)carbonyl]phenyl}carboxamide hydrochloride) and a novel crystalline form of a hydrate or solvate of the compound. Further provided are a manufacturing method of the compound and crystalline form, a related intermediate, a pharmaceutical composition comprising the compound, an application using the compound or the crystalline form for preparing a pharmaceutical product for treating a disease, symptom, or disorder, and a therapeutic method for treating a disease, symptom, or disorder.

Abstract: Interface circuitry of an apparatus receives a first service data packet that includes at least first information for a first multimedia presentation frame and second information for a second multimedia presentation frame. Processing circuitry of the apparatus stores the first information and the second information in different rows having different row number in a service data table. Then the processing circuitry determines, from a preset database, first material data for the first multimedia presentation frame and second material data for the multimedia presentation frame based on material configuration information in the first service data packet. Further the processing circuitry associates the first material data and the second material data in a material data table with different row numbers in the service data table and generates first multimedia service data corresponding to the first service data packet based on the association between the service data table and the material data table.

Abstract: Provided are a compound as represented by structural formula (I) ({5 -[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-6-aminopyridazin-3-yl}-N-{4-[((3S,5R)-3,5-di methylpiperazinyl)carbonyl]phenyl}carboxamide hydrochloride) and a novel crystalline form of a hydrate or solvate of the compound. Further provided are a manufacturing method of the compound and crystalline form, a related intermediate, a pharmaceutical composition comprising the compound, an application using the compound or the crystalline form for preparing a pharmaceutical product for treating a disease, symptom, or disorder, and a therapeutic method for treating a disease, symptom, or disorder.